Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | F13A1 | P00488 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | THPO | P40225 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CASP2 | P42575 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525320 | 1.00 | PAOX (0.49) | PAOXMAOAMAOBCYP1A2ALOX15 | |
| Trifluoroacetic Acid SCHEMBL9178312 | 0.89 | HDAC6 (0.51) | PAOXMAOAMAOBCYP1A2ALOX15 | |
| Trifluoroacetic Acid SCHEMBL9173127 | 0.89 | HDAC6 (0.51) | PAOXMAOAMAOBCYP1A2ALOX15 | |
| SCHEMBL28263835 | 0.89 | CYP1A2 (0.59) | PAOXCYP1A2ALOX15CA12F13A1 | |
| SCHEMBL525137 | 0.88 | PAOX (0.47) | PAOXMAOAMAOBCYP1A2ALOX15 | |
| SCHEMBL524786 | 0.88 | PAOX (0.47) | PAOXMAOAMAOBCYP1A2ALOX15 | |
| Spermidine SCHEMBL10634413 | 0.87 | CYP1A2 (0.61) | PAOXMAOAMAOBCYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL9173275 | 0.86 | UBE2N (0.47) | PAOXMAOAMAOBCYP1A2ALOX15 | |
| SCHEMBL25189618 | 0.85 | CYP1A2 (0.56) | PAOXMAOAMAOBCYP1A2ALOX15 | |
| SCHEMBL14262157 | 0.85 | CA12 (0.52) | CYP1A2ALOX15CA12F13A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190278-A1 | Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases | LABORATOIRES FOURNIER SA (FR) | 2013-07-25 | — | — | US | disclosed |
| EP-2598131-A1 | COMPOUNDS FOR THE TREATMENT/PREVENTION OF OCULAR INFLAMMATORY DISEASES | Laboratoires Fournier S.A. (FR) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013884-A1 | COMPOUNDS FOR THE TREATMENT/PREVENTION OF OCULAR INFLAMMATORY DISEASES | LABORATOIRES FOURNIER SA (FR) | 2012-02-02 | — | — | WO | disclosed |
| EP-0600762-B1 | Analogues of the 15-deoxyspergualine, process for their preparation and their use as immunosuppresants | FOURNIER IND & SANTE (FR) | 1996-07-10 | — | — | EP | disclosed |
| EP-0600762-A1 | Analogues of the 15-deoxyspergualine, process for their preparation and their use as immunosuppresants | FOURNIER INDUSTRIE ET SANTE (FR) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190278-A1 | Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases | TNF, NFKBIA, ALDH1A2 | PAOX 1954/4885MAOA 1819/4885MAOB 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.